A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)
Purpose
The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.
Condition
- Healthy
Eligibility
- Eligible Ages
- Between 19 Years and 55 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
The main inclusion criteria include but are not limited to the following: - Is in good health before randomization - Has a body mass index (BMI) ≥18 and ≤32 kg/m^2, inclusive
Exclusion Criteria
The main exclusion criteria include but are not limited to the following: - Has a history or presence of clinically significant medical or psychiatric condition or disease - Has a history of cancer
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Crossover Assignment
- Primary Purpose
- Basic Science
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental MK-7262 |
Participants will receive MK-7262 orally. |
|
|
Experimental Enlicitide |
Participants will receive enlicitide orally. |
|
|
Experimental MK-7262 plus Enlicitide |
Participants will receive MK-7262 and enlicitide orally. |
|
Recruiting Locations
Celerion ( Site 0001)
Lincoln, Nebraska 68502
Lincoln, Nebraska 68502
Contact:
Study Coordinator
402-476-2811
Study Coordinator
402-476-2811
More Details
- Status
- Recruiting
- Sponsor
- Merck Sharp & Dohme LLC